These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 28583909)
41. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305 [TBL] [Abstract][Full Text] [Related]
42. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467 [TBL] [Abstract][Full Text] [Related]
43. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331 [TBL] [Abstract][Full Text] [Related]
46. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581 [TBL] [Abstract][Full Text] [Related]
47. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T; Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758 [TBL] [Abstract][Full Text] [Related]
48. [Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]. Koual M; Perkins G; Delanoy N; Crespel C; Medioni J; Nguyen-Xuan HT; Douay-Hauser N; Blons H; Le Frère-Belda MA; Molière D; Achen G; Nos C; Balaya V; Montero R; Laurent-Puig P; Bats AS Ann Pathol; 2020 Apr; 40(2):70-77. PubMed ID: 32046878 [TBL] [Abstract][Full Text] [Related]
49. Olaparib, a new hope for ovarian cancer. Samoon Z; Jabbar AA Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438 [No Abstract] [Full Text] [Related]
50. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Gunderson CC; Moore KN Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679 [TBL] [Abstract][Full Text] [Related]
51. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report. Wu C; Fan M; Hu Y Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603 [TBL] [Abstract][Full Text] [Related]
52. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Munroe M; Kolesar J Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701 [TBL] [Abstract][Full Text] [Related]
53. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264 [TBL] [Abstract][Full Text] [Related]
54. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
55. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146 [TBL] [Abstract][Full Text] [Related]
56. Identification of Somatically Acquired Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788 [TBL] [Abstract][Full Text] [Related]
57. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382 [TBL] [Abstract][Full Text] [Related]
58. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476 [TBL] [Abstract][Full Text] [Related]
59. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468 [TBL] [Abstract][Full Text] [Related]
60. Clinical Response to Olaparib in a Patient With Leptomeningeal Carcinomatosis in Newly Diagnosed Breast Cancer With Germline Shah M; Green J; Hudacko R; Cohen AJ JCO Precis Oncol; 2024 Jul; 8():e2400063. PubMed ID: 38991180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]